Gyre Therapeutics, Inc. Income Statement

Income Statement Dec2009 Dec2010 Dec2011 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 25.06M85.71M97.64M57.86M0.52M1.81M1.75M0.40M1.02M0.01M-0.01M20.95M7.34M102.29M113.45M105.76M
Cost of Revenue 0.69M6.06M7.38M54.24M61.16M57.51M
Gross Profit 24.37M85.71M97.64M57.86M0.52M1.81M1.75M0.40M1.02M0.01M-0.01M14.89M-0.04M48.05M108.81M101.87M
Operating items
Research & Development 40.18M64.55M95.22M49.09M6.56M5.27M5.96M11.55M12.85M21.47M43.86M52.98M68.89M16.69M13.78M12.02M
Selling, General & Administrative 8.17M8.05M12.17M13.19M4.09M4.05M9.59M9.26M9.99M12.35M13.42M16.18M18.96M17.37M14.66M16.11M
Other Operating Expenses 17.04M3.72M2.23M-0.00M-0.12M9.16M7.38M57.19M-2.71M61.46M
Operating Expenses 65.39M72.60M107.38M66.00M10.64M9.32M15.55M20.82M22.84M33.83M57.28M78.32M95.23M93.09M180.68M89.59M
Operating Income -40.33M13.12M-9.74M-8.14M-10.12M-7.51M-13.80M-20.42M-21.82M-33.82M-57.28M-57.37M-87.89M9.20M-67.23M16.16M
EBIT -40.33M13.12M-9.74M-8.14M-10.12M-7.51M-13.80M-20.42M-21.82M-33.82M-57.28M-57.37M-87.89M9.20M-67.23M16.16M
Non-operating items
Interest & Investment Income 1.05M1.46M1.35M1.07M0.15M0.90M0.52M3.47M0.26M3.77M2.15M1.13M0.04M0.72M
Other Non Operating Income 0.13M0.09M-0.00M1.65M-0.04M-0.09M-0.08M0.86M-1.52M-1.66M
Non Operating Income 0.83M1.31M1.22M1.04M0.52M0.57M0.13M0.09M-0.00M1.65M-0.04M-0.09M-0.08M-1.52M-1.66M
Net income details
EBT -39.49M14.43M-8.53M-7.10M-46.70M-29.14M-14.78M-16.95M-21.56M-30.05M-55.14M-56.33M-87.93M9.41M-76.97M23.22M
Tax Provisions 0.09M-3.53M-0.10M0.01M3.48M5.99M9.35M6.32M
Profit After Tax -39.40M10.90M-8.53M-7.00M-9.97M-6.61M-14.76M-16.95M-21.56M-30.05M-55.18M-56.24M-87.93M4.31M-85.48M17.90M
Income from Non-Controlling Interests 2.01M7.45M5.81M
Income from Continuing Operations -39.58M17.95M-8.53M-7.00M-46.70M-32.62M-14.78M-16.95M-21.56M-30.05M-55.14M-56.33M-87.93M3.42M-86.31M16.90M
Consolidated Net Income -39.58M17.95M-8.53M-7.00M-46.70M-32.62M-14.78M-16.95M-21.56M-30.05M-55.14M-56.33M-87.93M3.42M-86.31M16.90M
Income towards Parent Company -39.58M17.95M-8.53M-7.00M-46.70M-32.62M-14.78M-16.95M-21.56M-30.05M-55.14M-56.33M-87.93M3.42M-86.31M16.90M
Preferred Dividend Payments 3.95M
Net Income towards Common Stockholders -39.58M17.95M-8.53M-7.00M-46.70M-32.62M-14.78M-16.95M-25.51M-30.05M-55.18M-56.24M-87.93M2.30M-92.93M12.09M
Additional items
EPS (Basic) -0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M
EPS (Weighted Average and Diluted) -0.00M0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M
Shares Outstanding (Weighted Average) 0.02M0.02M0.02M0.02M0.02M0.02M0.05M0.05M0.29M0.80M0.80M1.47M2.09M2.10M2.53M93.52M
Shares Outstanding (Diluted Average) 25.64M30.15M31.64M30.64M31.55M
EBITDA -40.33M11.12M-8.72M-6.83M-46.82M-32.71M-13.80M-20.42M-21.82M-33.82M-57.28M-57.37M-87.89M9.20M-67.23M16.16M
Tax Rate 1.42%63.62%27.23%